TSH Calibration and Potency: Immunoreactivity, Receptor Binding, and Bioactivity

Abstract

Thyroid-stimulating hormone (TSH) can be described by protein mass, molar amount, immunoreactivity, receptor-binding activity, or cell-based biological potency, but these quantities are not automatically interchangeable. A preparation with the same nominal protein concentration as another preparation can produce a different signal because intact heterodimer content, glycosylation, species origin, aggregation, receptor system, and assay conditions influence measured activity. This technical note explains how to calibrate and compare TSH preparations without treating one assay output as a universal property of the molecule. Particular attention is given to bovine TSH (bTSH) used in thyroid research, where mass concentration and functional activity should be documented separately whenever possible.

Keywords

TSH calibration, TSH potency, immunoreactivity, receptor binding, cAMP bioactivity, relative potency, reference standard, International Unit, glycoform, bovine TSH

1. Why TSH Concentration and Potency Are Not Identical

Concentration describes how much material is present according to a defined measurement system. Potency describes the ability of that material to produce a defined biological effect relative to a reference preparation. For a glycoprotein hormone such as TSH, these properties can diverge because molecular heterogeneity changes antibody recognition, receptor engagement, signaling efficiency, and metabolic behavior.

A protein assay may count intact heterodimer, partially degraded protein, inactive conformers, and related protein material together. An ELISA may preferentially detect epitopes on intact or partially intact TSH. A receptor-binding assay measures recognition by TSHR but not necessarily signal transduction. A cAMP bioassay measures a downstream functional response in a specific cellular system. Therefore, TSH calibration must always be tied to the method used to assign the value.

Measurement	What It Describes	Typical Output	Main Limitation
Protein mass	Total protein assigned to the preparation	ug/mL, ng/mL	Does not distinguish active from inactive material
Molar concentration	Estimated number of molecules	nM, pM	Depends on molecular-weight assumptions and molecular integrity
Immunoreactivity	Recognition by assay antibodies	mIU/L or assay-calibrated concentration	Epitope and calibrator dependent
Receptor binding	Ability to occupy TSHR	IC50, EC50, relative binding activity	Binding does not prove productive signaling
Bioactivity	Functional response in a defined system	EC50, Emax, IU, relative potency	Cell line and assay conditions affect the result

2. Protein Mass, Molar Concentration, and International Units

Mass units are useful for reagent preparation and material balance. Molar units can support mechanistic comparisons when molecular weight and intact hormone content are sufficiently defined. International Units (IU), by contrast, are assigned through reference standards and collaborative calibration; they are not simply a molecular-weight conversion of grams or moles.

For glycoprotein hormones, an IU is best understood as an assigned unit linked to a physical reference preparation. It is useful when physicochemical mass alone does not adequately express a biologically or diagnostically meaningful quantity. A laboratory should therefore avoid calculating IU from protein concentration unless a validated, preparation-specific relationship has been established against an appropriate TSH reference preparation.

Figure 1. TSH can be quantified at multiple analytical and functional layers. Agreement between layers must be demonstrated rather than assumed.

3. Immunoreactivity Measured by ELISA

ELISA and related ligand-binding immunoassays quantify antigen recognition by a defined antibody pair. The result depends on calibrator assignment, antibody epitopes, assay architecture, incubation conditions, and the molecular forms recognized. Two TSH preparations can therefore give similar ELISA values while differing in receptor potency, particularly when glycoforms, subunit integrity, or conformational states differ.

When using immunoreactivity as a release or comparison attribute, document the calibrator source, assay format, standard-curve model, matrix, dilution procedure, and reporting unit. Treat the value as assay-specific unless commutability across preparations has been demonstrated.

Interpretation Rule

Immunoreactivity answers an antibody-recognition question. It should not be labeled as bioactive TSH unless a functional relationship has been established in the same preparation set.

4. Receptor-Binding Activity

Receptor-binding assays test whether TSH can interact with TSHR. Formats may use native thyroid membranes, recombinant receptor preparations, intact receptor-expressing cells, or competition against a labeled ligand. Binding data are commonly expressed as IC50, apparent affinity, or relative binding activity against a reference.

Receptor recognition is biologically closer to function than ELISA, but it is still not equivalent to signaling. Classic deglycosylation studies showed that carbohydrate removal can preserve substantial receptor recognition while reducing downstream cAMP activity. This distinction is particularly important when comparing glycoforms or assessing TSH receptor-binding activity after processing, storage, or structural modification.

Assay Type	Primary Question	Common Metric	What It Cannot Establish Alone
ELISA	Is the antigen recognized by antibodies?	Concentration or immunoreactive units	Receptor engagement or signaling
TSHR binding	Does the preparation occupy TSHR?	IC50, Ki, relative binding	Magnitude of downstream functional response
Cell-based cAMP	Does receptor engagement produce signaling?	EC50, Emax, relative potency	In vivo half-life or pharmacodynamic duration

5. Cell-Based cAMP Bioactivity

TSHR activation is commonly quantified through Gs-dependent cAMP accumulation or a cAMP-responsive reporter. In a suitable TSHR-expressing cell system, a concentration-response curve provides EC50, maximal response, and, when compared with a reference preparation, relative potency.

Cell-based TSH cAMP bioactivity is sensitive to receptor expression, cell passage, phosphodiesterase activity, stimulation time, serum background, plate density, and readout technology. The same material can therefore produce different EC50 values across laboratories unless the assay is standardized. For lot comparison, the most defensible approach is to test reference and sample in the same run under the same cell and detection conditions.

6. Relative Potency and Reference Preparations

Relative potency expresses how much of a test preparation is required to produce the same defined response as a reference preparation. It is more informative than comparing raw EC50 values when curves have different plate-to-plate baselines or detection scales.

A laboratory working standard should be characterized against an external or higher-order reference when appropriate, then qualified for the intended assay. Once established, the internal standard can be included routinely to monitor system suitability and lot continuity. The identity, storage history, reconstitution procedure, and assigned value of the TSH potency reference should be controlled because reference drift directly affects reported potency.

Reference Level	Purpose	Typical Frequency	Key Documentation
International or primary reference	Higher-order calibration and unit continuity	Periodic qualification	Official identity, assigned unit, instructions for use
Internal reference standard	Routine relative potency assignment	Each potency campaign or run series	Bridging data, stability, storage, requalification
Run control	Detect day-to-day assay drift	Every plate or run	Acceptance range and trend chart

7. Parallel-Line and Dose-Response Comparison

Relative potency is meaningful only when the reference and test preparation behave similarly enough that a common response model is justified. For sigmoidal cell-based assays, 4-parameter logistic (4PL) or 5-parameter logistic (5PL) models are commonly used. Parallelism can be assessed by comparing slopes or by fitting constrained and unconstrained models according to a prespecified statistical plan.

Failure of parallelism is not merely a statistical inconvenience. It can indicate matrix interference, receptor partial agonism, altered glycoform composition, degradation, different maximal efficacy, or a concentration-dependent artifact. In that situation, reporting a single relative-potency number can conceal biologically important differences.

Recommended Comparison Sequence

Confirm adequate curve span and monotonic response, evaluate reference and sample curves independently, assess similarity or parallelism, then calculate relative potency only when the model assumptions are satisfied.

8. The Role of International TSH Standards

International standards provide a common reference framework, but the intended use of a particular standard matters. The current NIBSC listing identifies human pituitary TSH 81/615 as the 4th WHO International Standard for immunoassay and notes that it replaces 81/565. Separately, recombinant human TSH 03/192 is the 1st International Standard for calibration of TSH preparations by bioassay.

This distinction illustrates a central calibration principle: a standard is selected because it is fit for a defined measurement purpose. An immunoassay standard supports continuity of immunoreactive measurement; a bioassay standard supports biological activity calibration. Laboratories should not assume that an IU assigned in one context can be transferred to a different assay principle without validation.

Reference Material	Material Type	Primary Intended Use	Practical Implication
WHO/NIBSC 81/615	Human pituitary TSH	Immunoassay calibration	Supports immunoreactive TSH measurement continuity
WHO/NIBSC 03/192	Recombinant human TSH	Bioassay calibration	Supports biological potency assignment in functional assays
Laboratory working standard	Assay-specific material	Routine calibration and trending	Must be bridged to the intended reference framework

Figure 2. A reference hierarchy is most useful when it preserves the meaning of the measurement rather than forcing unlike assay outputs into a single unit.

9. Species and Glycoform Effects on Calibration

TSH is structurally heterogeneous because both amino-acid sequence and glycosylation can vary with species, expression system, physiological state, and purification history. These differences can change antibody recognition, receptor affinity, maximal signaling, and clearance. Bovine TSH is a well-known example: it can display stronger signaling at the human TSH receptor than human TSH in some systems, so equal mass does not imply equal functional stimulation.

Glycosylation can also uncouple receptor recognition from signaling. Experimental deglycosylation of bovine thyrotropin has been reported to preserve receptor recognition to a substantial degree while reducing full biological activity. Calibration strategies should therefore consider whether the reference and test preparations are structurally comparable enough for the intended assay.

Source of Difference	Possible Effect on Immunoassay	Possible Effect on Binding	Possible Effect on Bioactivity
Species sequence	Changes epitope recognition	May alter receptor affinity	May alter EC50 and Emax
Glycan composition	May mask or expose epitopes	Can change apparent affinity	Can change signaling efficiency and persistence
Subunit dissociation	Assay dependent	Usually reduces productive recognition	Reduces functional hormone content
Aggregation or degradation	May create assay-specific bias	Can distort avidity or availability	Can reduce or unpredictably alter response

10. Reporting Assay-Specific TSH Results

A complete TSH result should communicate both the number and the measurement context. Reporting only "TSH = 10" without assay type, units, reference material, and matrix is not sufficient for cross-study interpretation.

Result Type	Recommended Reporting Elements	Example
Protein concentration	Method, protein basis, concentration unit	25 ug/mL by validated protein assay
Immunoreactivity	Assay format, calibrator, unit, matrix	Immunoreactive TSH, mIU/L, calibrated to defined standard
Receptor binding	Receptor source, ligand format, IC50 or relative binding	Relative TSHR binding = 0.82 vs. internal reference
Cell bioactivity	Cell line, receptor, endpoint, curve model, relative potency	Relative cAMP potency = 1.18, 95% CI stated

For research reagents, it is often useful to report both a compositional value and a functional value. This provides a more transparent description of a preparation than either measurement alone.

11. Establishing Internal Reference Controls

Internal reference controls stabilize a laboratory's own assay over time. Select a homogeneous, sufficiently stable lot; assign it a value by comparison with the chosen external reference or legacy standard; aliquot to minimize freeze-thaw exposure; and establish acceptance ranges using repeated independent runs.

Trend EC50, Emax, slope, background, and calculated relative potency rather than relying on one QC number. For a TSH internal reference control, requalification should be triggered by evidence of drift, storage excursion, new cell bank, major reagent change, or replacement of the working standard.

Control Attribute	What to Track	Why It Matters
Identity and lot	Source, lot number, preparation history	Maintains traceable continuity
Storage	Temperature, aliquot size, freeze-thaw cycles	Reduces potency drift
Curve performance	EC50, Emax, Hill slope, background	Detects assay-system changes
Potency assignment	Relative potency with confidence interval	Supports quantitative lot comparison
Requalification	Bridge old and new standard lots	Prevents step changes in reported values

12. Avoiding Unsupported Conversion Between Assay Units

The most common calibration error is to convert between mass, immunoreactive units, receptor-binding units, and bioactivity units as though a universal constant connects them. Such a conversion is only defensible when it has been experimentally established for the same preparation or a demonstrably commutable set of preparations under a defined assay system.

Do not infer cell potency from ELISA concentration, do not infer receptor affinity from protein mass, and do not convert a bovine TSH mass value into human TSH IU using a generic molecular-weight calculation. If two unit systems must be related, generate a preparation-specific bridging study across multiple concentrations and lots, evaluate parallelism and uncertainty, and report the relationship as method dependent rather than universal.

Bottom Line

TSH potency is an assay-defined biological property. A value is interpretable only when the reference material, assay principle, unit definition, and experimental system are stated together.

References

Gaines Das, R. E., & Bristow, A. F. (1985). The Second International Reference Preparation of Thyroid-Stimulating Hormone, Human, for Immunoassay: calibration by bioassay and immunoassay in an international collaborative study. Journal of Endocrinology, 104(3), 367-379. https://doi.org/10.1677/joe.0.1040367.
Rafferty, B., & Gaines Das, R. (1999). Comparison of pituitary and recombinant human thyroid-stimulating hormone (rhTSH) in a multicenter collaborative study: establishment of the first World Health Organization reference reagent for rhTSH. Clinical Chemistry, 45(12), 2207-2215. https://doi.org/10.1093/clinchem/45.12.2207.
Thienpont, L. M., Van Uytfanghe, K., Beastall, G., Faix, J. D., Ieiri, T., Miller, W. G., Nelson, J. C., Ronin, C., Ross, H. A., Thijssen, J. H., & Toussaint, B. (2010). Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. Clinical Chemistry, 56(6), 902-911. https://doi.org/10.1373/clinchem.2009.140178.
Estrada, J. M., Soldin, D., Buckey, T. M., Burman, K. D., & Soldin, O. P. (2014). Thyrotropin isoforms: implications for thyrotropin analysis and clinical practice. Thyroid, 24(3), 411-423. https://doi.org/10.1089/thy.2013.0119.
Mueller, S., Kleinau, G., Szkudlinski, M. W., Jaeschke, H., Krause, G., & Paschke, R. (2009). The superagonistic activity of bovine thyroid-stimulating hormone and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor. Journal of Biological Chemistry, 284(24), 16317-16324. https://doi.org/10.1074/jbc.M109.005710.
World Health Organization. (2023). WHO 4th International Standards for TSH (human, pituitary). WHO/BS/2023.2454.
International Council for Harmonisation. (2022). ICH M10: Bioanalytical Method Validation and Study Sample Analysis.